Novo Nordisk Signals 2026 Push After Amycretin Posts Major Phase 2 Gains In Type 2 Diabetes PatientsBenzinga • 11/25/25
Novo Nordisk Stock Jumps on Positive Weight-Loss Drug Data. Why It Deserves Better.Barrons • 11/25/25
Novo Nordisk's Longshot Alzheimer's Trial Didn't Work, But It Is Still Worth BuyingSeeking Alpha • 11/25/25
Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetesGlobeNewsWire • 11/25/25
Novo Nordisk Faces Setback. Here's What Caused the Ozempic Maker's Stock to Tumble Monday.Investopedia • 11/24/25
Novo Nordisk shares slide after semaglutide Alzheimer's trial misses primary goalProactive Investors • 11/24/25
Will NVO's U.S. Price Cuts Boost Access & Revive Semaglutide Demand?Zacks Investment Research • 11/24/25
Holiday air travel, Novo Nordisk trial results, 'Wicked: For Good' debut and more in Morning SquawkCNBC • 11/24/25
Novo Nordisk, Waldencast And Other Big Stocks Moving Lower In Monday's Pre-Market SessionBenzinga • 11/24/25
Novo Nordisk shares plunge as oral semaglutide Alzheimer's trial fails to show clinical benefitInvezz • 11/24/25